[1]
|
Dumesic DA, Oberfield SE, Stener-Victorin E, et al. (2015) Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev 36: 487-525. doi: 10.1210/er.2015-1018
|
[2]
|
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81: 19-25.
|
[3]
|
Brennan L, Teede H, Skouteris H, et al. (2017) Lifestyle and behavioral management of polycystic ovary syndrome. J Womens Health (Larchmt) 26: 836-848. doi: 10.1089/jwh.2016.5792
|
[4]
|
Teede H, Misso M, Costello M, et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome, 2018. Available from: https://www.monash.edu/__data/assets/pdf_file/0004/1412644/PCOS_Evidence-Based-Guidelines_20181009.pdf.
|
[5]
|
Costello MF, Misso M, Balen AH, et al. (2019) A brief update on the evidence supporting the treatment of infertility in polycystic ovary syndrome. Aust N Z J Obstet Gynaecol 59: 867-873. doi: 10.1111/ajo.13051
|
[6]
|
Tay CT, Moran LJ, Wijeyaratne CN, et al. (2018) Integrated model of care for polycystic ovary syndrome. Semin Reprod Med 36: 86-94. doi: 10.1055/s-0038-1667310
|
[7]
|
Conway G, Dewailly D, Diamanti-Kandarakis E, et al. (2014) European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire. Eur J Endocrinol 171: 489-498. doi: 10.1530/EJE-14-0252
|
[8]
|
Blackshaw LCD, Chhour I, Stepto NK, et al. (2019) Barriers and facilitators to the implementation of evidence-based lifestyle management in polycystic ovary syndrome: a narrative review. Med Sci (Basel) 7: 76.
|
[9]
|
Arasu A, Moran LJ, Robinson T, et al. (2019) Barriers and facilitators to weight and lifestyle management in women with polycystic ovary syndrome: general practitioners' perspectives. Nutrients 11: 1024. doi: 10.3390/nu11051024
|
[10]
|
Taylor T, Scott A (2019) Do physicians prefer to complete online or mail surveys? Findings from a national longitudinal survey. Eval Health Prof 42: 41-70. doi: 10.1177/0163278718807744
|
[11]
|
Beebe TJ, Locke GR, Barnes SA, et al. (2007) Mixing web and mail methods in a survey of physicians. Health Serv Res 42: 1219-1234. doi: 10.1111/j.1475-6773.2006.00652.x
|
[12]
|
Cunningham CT, Quan H, Hemmelgarn B, et al. (2015) Exploring physician specialist response rates to web-based surveys. BMC Med Res Methodol 15: 32. doi: 10.1186/s12874-015-0016-z
|
[13]
|
Jatic Z, Erkocevic H, Trifunovic N, et al. (2019) Frequency and forms of workplace violence in primary health care. Med Arch 73: 6-10. doi: 10.5455/medarh.2019.73.6-10
|
[14]
|
Piltonen TT, Ruokojarvi M, Karro H, et al. (2019) Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe. PLoS One 14: e0226074. doi: 10.1371/journal.pone.0226074
|
[15]
|
Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33: 981-1030. doi: 10.1210/er.2011-1034
|
[16]
|
Saxena P, Prakash A, Nigam A, et al. (2012) Polycystic ovary syndrome: is obesity a sine qua non? A clinical, hormonal, and metabolic assessment in relation to body mass index. Indian J Endocrinol Metab 16: 996-999. doi: 10.4103/2230-8210.103011
|
[17]
|
Lewandowski KC, Skowrońska-Jóźwiak E, Łukasiak K, et al. (2019) How much insulin resistance in polycystic ovary syndrome? Comparison of HOMA-IR and insulin resistance (Belfiore) index models. Arch Med Sci 15: 613-618. doi: 10.5114/aoms.2019.82672
|
[18]
|
Singla R, Gupta Y, Khemani M, et al. (2015) Thyroid disorders and polycystic ovary syndrome: An emerging relationship. Indian J Endocrinol Metab 19: 25-29. doi: 10.4103/2230-8210.146860
|
[19]
|
Tomlinson J, Pinkney J, Adams L, et al. (2017) The diagnosis and lived experience of polycystic ovary syndrome: A qualitative study. J Adv Nurs 73: 2318-2326. doi: 10.1111/jan.13300
|
[20]
|
Gibson-Helm ME, Lucas IM, Boyle JA, et al. (2014) Women's experiences of polycystic ovary syndrome diagnosis. Fam Pract 31: 545-549. doi: 10.1093/fampra/cmu028
|
[21]
|
Barry JA, Kuczmierczyk AR, Hardiman PJ (2011) Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 26: 2442-2451. doi: 10.1093/humrep/der197
|
[22]
|
Blay SL, Aguiar JV, Passos IC (2016) Polycystic ovary syndrome and mental disorders: a systematic review and exploratory meta-analysis. Neuropsychiatr Dis Treat 12: 2895-2903. doi: 10.2147/NDT.S91700
|
[23]
|
Brutocao C, Zaiem F, Alsawas M, et al. (2018) Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine 62: 318-325. doi: 10.1007/s12020-018-1692-3
|
[24]
|
Cooney LG, Lee I, Sammel MD, et al. (2017) High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 32: 1075-1091. doi: 10.1093/humrep/dex044
|
[25]
|
Damone AL, Joham AE, Loxton D, et al. (2019) Depression, anxiety and perceived stress in women with and without PCOS: a community-based study. Psychol Med 49: 1510-1520. doi: 10.1017/S0033291718002076
|
[26]
|
Dokras A, Stener-Victorin E, Yildiz BO, et al. (2018) Androgen Excess-Polycystic Ovary Syndrome Society: position statement on depression, anxiety, quality of life, and eating disorders in polycystic ovary syndrome. Fertil Steril 109: 888-899. doi: 10.1016/j.fertnstert.2018.01.038
|
[27]
|
Banting LK, Gibson-Helm M, Polman R, et al. (2014) Physical activity and mental health in women with polycystic ovary syndrome. BMC Women's Health 14: 51. doi: 10.1186/1472-6874-14-51
|
[28]
|
Lamb JD, Johnstone EB, Rousseau JA, et al. (2011) Physical activity in women with polycystic ovary syndrome: prevalence, predictors, and positive health association. Am J Obstet Gynecol 204: 352.e1-352.e6. doi: 10.1016/j.ajog.2010.12.006
|
[29]
|
Gibson-Helm M, Teede H, Dunaif A, et al. (2017) Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 102: 604-612.
|
[30]
|
Pasquali R (2018) Contemporary approaches to the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab 9: 123-134. doi: 10.1177/2042018818756790
|
[31]
|
Johnson NP (2014) Metformin use in women with polycystic ovary syndrome. Ann Transl Med 2: 56.
|
[32]
|
Middleton KR, Anton SD, Perri MG (2013) Long-term adherence to health behavior change. Am J Lifestyle Med 7: 395-404. doi: 10.1177/1559827613488867
|
[33]
|
Seo DC, Sa J (2008) A meta-analysis of psycho-behavioral obesity interventions among US multiethnic and minority adults. Prev Med 47: 573-582. doi: 10.1016/j.ypmed.2007.12.010
|
[34]
|
Welschen LM, van Oppen P, Dekker JM, et al. (2007) The effectiveness of adding cognitive behavioural therapy aimed at changing lifestyle to managed diabetes care for patients with type 2 diabetes: design of a randomised controlled trial. BMC Public Health 7: 74. doi: 10.1186/1471-2458-7-74
|
[35]
|
Moran LJ, Ko H, Misso M, et al. (2013) Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Diet 113: 520-545. doi: 10.1016/j.jand.2012.11.018
|
[36]
|
Zhang X, Zheng Y, Guo Y, et al. (2019) The Effect of low carbohydrate diet on polycystic ovary syndrome: A meta-analysis of randomized controlled trials. Int J Endocrinol 2019: 1-14.
|
[37]
|
Farshchi H, Rane A, Love A, et al. (2007) Diet and nutrition in polycystic ovary syndrome (PCOS): pointers for nutritional management. J Obstet Gyneacol 27: 762-773. doi: 10.1080/01443610701667338
|
[38]
|
Ko H, Teede H, Moran L (2016) Analysis of the barriers and enablers to implementing lifestyle management practices for women with PCOS in Singapore. BMC Res Notes 9: 311. doi: 10.1186/s13104-016-2107-2
|
[39]
|
Racic M, Pekez-Pavlisko T, Jokovic S (2018) Barriers and facilitators for implementation of family medicine-oriented model of primary care in Bosnia and Herzegovina: A qualitative study. Int J Health Plann Manage 33: e378-e390. doi: 10.1002/hpm.2470
|
[40]
|
Fang F, Ni K, Cai Y, et al. (2017) Effect of vitamin D supplementation on polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Clin Pract 26: 53-60. doi: 10.1016/j.ctcp.2016.11.008
|
[41]
|
Jamilian M, Foroozanfard F, Rahmani E, et al. (2017) Effect of two different doses of vitamin D supplementation on metabolic profiles of insulin-resistant patients with polycystic ovary syndrome. Nutrients 9: 1280. doi: 10.3390/nu9121280
|
[42]
|
Menichini D, Facchinetti F (2020) Effects of vitamin D supplementation in women with polycystic ovary syndrome: a review. Gynecol Endocrinol 36: 1-5. doi: 10.1080/09513590.2019.1625881
|
[43]
|
Kadoura S, Alhalabi M, Nattouf AH (2019) Effect of calcium and vitamin D supplements as an adjuvant therapy to metformin on menstrual cycle abnormalities, hormonal profile, and IGF-1 system in polycystic ovary syndrome patients: a randomized, placebo-controlled clinical trial. Adv Pharmacol Sci 2019.
|
[44]
|
Foroozanfard F, Jamilian M, Bahmani F, et al. (2015) Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. Clin Endocrinol (Oxf) 83: 888-894. doi: 10.1111/cen.12840
|
[45]
|
Tehrani HG, Mostajeran F, Shahsavari S (2014) The effect of calcium and vitamin D supplementation on menstrual cycle, body mass index and hyperandrogenism state of women with polycystic ovarian syndrome. J Res Med Sci 19: 875-880.
|
[46]
|
Izadi A, Ebrahimi S, Shirazi S, et al. (2019) Hormonal and metabolic effects of coenzyme Q10 and/or vitamin E in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 104: 319-327.
|
[47]
|
Izadi A, Shirazi S, Taghizadeh S, et al. (2019) Independent and additive effects of coenzyme Q10 and vitamin E on cardiometabolic outcomes and visceral adiposity in women with polycystic ovary syndrome. Arch Med Res 50: 1-10. doi: 10.1016/j.arcmed.2019.04.004
|
[48]
|
Talari HR, Poladchang S, Hamidian Y, et al. (2018) The effects of omega-3 and vitamin E co-supplementation on carotid intima-media thickness and inflammatory factors in patients with polycystic ovary syndrome. Oman Med J 33: 473-479. doi: 10.5001/omj.2018.88
|
[49]
|
Ebrahimi FA, Samimi M, Foroozanfard F, et al. (2017) The effects of omega-3 fatty acids and vitamin E co-supplementation on indices of insulin resistance and hormonal parameters in patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Exp Clin Endocrinol Diabetes 125: 353-359. doi: 10.1055/s-0042-117773
|